• PN: A111215T

COMPONENTS

45x Ab-conjugated beads (S5P8 - human VEGF-A Ab-bead). PN: A111215TA. One vial containing 35 µL of anti-human VEGF-A conjugated to AimPlex Bead S5P8.

25x Biotin-detection Ab (human VEGF-A Biotin-dAb). PN: A111215TB. One vial containing 35 µL of biotinylated anti-human VEGF-A.

Lyophilized Standard Mix-Human Group 2 Panel B, 10-Plex. PN: HG20010. One vial containing lyophilized recombinant human IL-17F, IL-20, IL-21, IL-28A, IL-29, IL-33, M-CSF, MPO, TSLP, and VEGF-A. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human VEGF-A.  Can be multiplexed with other analytes in Human Group 2.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 2 pg/mL

Quantitation range:

LLOQ: < 5 pg/mL

ULOQ: > 2,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 2: Negligible

Sample volume: 15 µL/test

Description:

Vascular Endothelial Growth Factor A (VEGF-A) is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. As its name implies, VEGF-A activity has been studied mostly on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g., stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). In vitro, VEGF-A has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF-A functions as a vasodilator and increases microvascular permeability. It was originally referred to as vascular permeability factor. Diseases associated with VEGFA include microvascular complications of diabetes 1 and POEMS syndrome.

References:

1.      Mattei MG, Borg JP, Rosnet O, Marmé D, Birnbaum D (February 1996). "Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively". Genomics 32 (1): 168–169. doi:10.1006/geno.1996.0098. PMID 8786112.

2.      Mackenzie, Francesca, and Christiana Ruhrberg. "Diverse Roles for VEGF-A in the Nervous System." Development (n.d.): 1371-380. http://dev.biologist.org/. 15 Apr. 2012. Web. 19 Mar. 2013.

3.      Creuzet, Sophie, Gérard Couly, Christine Vincent, and Nicole M. Douarin. "Negative Effect of Hox Gene Expression on the Development of the Neural." Development (n.d.): 4301-313. http://dev.biologists.org/. 15 Sept. 2002. Web. 19 Mar. 2013.

4.      United States of America. Johns Hopkins University. http://omim.org. By Victor A. McKusick. Johns Hopkins University, 26 Feb. 2013. Web. 19 Mar. 2013.